Posted by Michael Wonder on 23 Jun 2016
New guidance from NICE recommends Humira (adalimumab), the only licensed biologic for treatment of hidradenitis suppurativa, a debilitating and disfiguring skin condition
22 June 2016 - AbbVie today announced that the NICE has published single technology appraisal guidance for the only licensed biologic medicine, Humira (adalimumab), for the treatment of hidradenitis suppurativa.
Adalimumab can be used in cases of active moderate to severe hidradenitis suppurativa in adult patients with an inadequate response to conventional systemic therapy (for example, antibiotics and steroids). The guidance notes that the treatment should be assessed after 12 weeks for evidence of a response. NICE’s approval means that patients in England and Wales, who are deemed clinically appropriate, now have the right to access this cost effective treatment via the NHS.
For more details, go to: http://www.abbvie.co.uk/content/dam/abbviecorp/uk/docs/press-releases/160621_AbbVie_NICE_TAG_PR.pdf
